期刊
FUTURE ONCOLOGY
卷 6, 期 12, 页码 1925-1936出版社
FUTURE MEDICINE LTD
DOI: 10.2217/FON.10.147
关键词
biliary tract cancer; Foscan (R); photodynamic therapy; Photofrin (R)
类别
资金
- Jubilaumsfonds der Osterreichischen Nationalbank (OeNB) [12677]
- Paracelsus Medical University Salzburg [08/07/037]
The prognosis of patients with nonresectable hilar biliary tract cancer (hBTC) is poor. Responsiveness to chemotherapy or radiochemotherapy is moderate at best, and patients are at a high risk of dying early from complications of local tumor infiltration (e. g., cholestasis, septic cholangitis, empyema or liver failure) rather than systemic disease. Therefore, palliative local therapy for the prevention of tumor complications plays a central role and still yields the longest survival times. Photodynamic therapy (PDT) is a local-ablative, tumor tissue-specific treatment currently representing the standard of care for nonresectable hBTC. Throughout the literature, PDT plus biliary drainage achieves median survival times in the range of 9-21 months (average 14-16 months), compared with approximately 6 months for drainage only. This article summarizes the recent advances in preclinical and clinical experience of PDT for hBTC, including experimental in vitro and in vivo studies, clinical studies and an overview of the ongoing clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据